Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…The French NS-PARK/FCRIN network: a 5-year balance sheet
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity. Background: The French Clinical Research Infrastructure network FCRIN is…Trends in first line therapy for PD in Wales: A 16 year observational study
Objective: To examine the changes in first line therapy of newly diagnosed Parkinson’s patients between 2000 and 2016 in Wales. Background: There have been several…A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)
Objective: Evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple oral LY3154207 (LY) doses in healthy subjects (HS) and persons with Parkinson’s disease (PWPD). Background:…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact of opicapone (OPC) on PDQ-39 in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a once-daily COMT…Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting
Objective: To explore the usefulness of wearable sensor data to inform treatment decisions in PD. Background: Wearable sensors are becoming increasingly incorporated into clinical care…Bdnf rs6265 and Other Variants Predict the Efficacy of Levodopa Monotherapy in Early-Stage Parkinson’s Disease
Objective: To determine whether relatively prevalent variants in the gene for brain-derived neurotrophic factor (Bdnf) are associated with differential efficacy of levodopa or other dopaminergic…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 34
- Next Page »